Viking Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian Lian
- Full Time Employees
- 65
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9920 Pacific Heights Boulevard San Diego CA United States of America 92121
- IPO Date
- Apr 28, 2015
- CIK
- 0001607678
- Website
- vikingtherapeutics.com
- Similar Companies
- Business
- Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for metabolic and endocrine disorders. Founded in 2012 and headquartered in San Diego, California, the company advances a pipeline targeting obesity, metabolic dysfunction-associated steatohepatitis (MASH), non-alcoholic fatty liver disease (NAFLD), lipid disorders, and rare diseases such as X-linked adrenoleukodystrophy (X-ALD). Its core programs include VK2735, a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist available in subcutaneous and oral formulations for obesity and related metabolic conditions; VK2809, an orally available small molecule selective thyroid hormone receptor beta (TR beta) agonist for MASH, fibrosis, NAFLD, and elevated low-density lipoprotein cholesterol (LDL-C); dual amylin and calcitonin receptor agonists (DACRAs) for obesity; and VK0214, an orally available selective TR beta agonist for X-ALD. Viking Therapeutics operates primarily in the United States with a focus on patients suffering from high unmet needs in metabolic and endocrine diseases, leveraging internal expertise in metabolism to drive innovation across its wholly-owned pipeline. The company's lead candidate, subcutaneous VK2735, advances in Phase 3 VANQUISH-1 and VANQUISH-2 registration trials for obesity in adults with and without type 2 diabetes, following positive Phase 2 VENTURE trial results; the oral formulation of VK2735 progresses in the Phase 2 VENTURE-Oral trial, with enrollment completed and data anticipated in the second half of 2025. VK2809 met primary and secondary endpoints in the Phase 2b VOYAGE trial for biopsy-confirmed MASH and fibrosis, building on prior Phase 2a data showing significant LDL-C and liver fat reductions; VK0214 demonstrated proof-of-concept in a Phase 1b trial for X-ALD by reducing very long-chain fatty acids. Recent developments include the completion of enrollment in the Phase 3 VANQUISH-1 trial for subcutaneous VK2735 in November 2025, alongside plans for a Phase 1 monthly dosing study in the third or fourth quarter of 2025 and an investigational new drug (IND) filing for its amylin agonist program in the fourth quarter of 2025. In March 2025, Viking secured a $150 million multi-year manufacturing agreement with CordenPharma to produce multiple metric tonnes of VK2735 annually, supporting over one billion oral pills or substantial injectable volumes to meet potential commercial demand. Phase 3 trials for subcutaneous VK2735 commenced in the second quarter of 2025, positioning the company to compete in the expanding obesity market dominated by GLP-1-based therapies.
Company News
Jupiter Topco LLC Makes New Investment in Viking Therapeutics, Inc. $VKTX
AXQ Capital LP Buys 56,796 Shares of Viking Therapeutics, Inc. $VKTX
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong
Viking Therapeutics to Participate at Upcoming Investor Conferences
Canada Pension Plan Investment Board Makes New Investment in Viking Therapeutics, Inc. $VKTX
Bank of New York Mellon Corp Takes Position in Viking Therapeutics, Inc. $VKTX
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of “Moderate Buy” by Brokerages
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
2 GLP-1 Stocks That Could Double Your Money by 2031
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP
Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript
Viking Therapeutics Q2 Earnings Call Highlights